

Amendments to the Claims

1-6. (Cancelled)

---

7. (Currently Amended) Isolated and purified biologically active TFPI ~~comprising an N-terminal amino acid sequence as shown in SEQ ID NO: 7, wherein the biologically active TFPI has an inhibitory concentration of at least 1 µg/ml in a prothrombin clotting assay, according to~~ made by a method comprising:

transforming yeast cells with a vehicle, said vehicle comprising a first nucleotide sequence encoding a first protein, wherein the first protein is TFPI, wherein the N-terminal amino acid sequence of the TFPI is SEQ ID NO: 7, said first nucleotide sequence being immediately preceded in frame by a second nucleotide sequence encoding a second protein ~~ubiquitin~~, the first and second nucleotide sequences together encoding a fusion protein;

incubating the transformed yeast cells under conditions ~~favorable for production of the~~ whereby the fusion protein is produced and cleaved to produce TFPI, wherein the TFPI is retained within the yeast cell;

preparing an insoluble fraction of the transformed yeast cells containing the TFPI; and recovering the TFPI from the insoluble fraction,

wherein the TFPI comprises the N-terminal amino acid sequence shown in SEQ ID NO:7 and wherein the TFPI has an inhibitory concentration of at least 1 µg/ml in a prothrombin clotting assay.

---

8-11. (Cancelled)

---

12. (New) The isolated and purified TFPI of claim 7 wherein the yeast cell of the method is a

*Saccharomyces cerevisiae* cell having a genotype selected from the group consisting of VH6, AB122, and JSC310.

13. (New) The method of claim 7 wherein the second protein is ubiquitin.

14. (New) The method of claim 7 wherein the second protein is superoxide dismutase.

---